Classic and Novel Signaling Pathways Involved in Cancer: Targeting the NF-κB and Syk Signaling Pathways

被引:16
作者
Tang, Cong [1 ]
Zhu, Guodong [1 ]
机构
[1] Xi An Jiao Tong Univ, Dept Urol, Affiliated Hosp 1, 277 Yanta West Rd, Xian 710061, Shaanxi, Peoples R China
关键词
NF-kappa B; Syk; signaling pathway; cancer; therapy; tumor necrosis factor; TRAF-INTERACTING PROTEIN; TYROSINE KINASE; SUPPRESSES OSTEOCLASTOGENESIS; TRANSCRIPTIONAL REGULATION; CYCLIN D1; ACTIVATION; IKK; SUBUNIT; P53; INFLAMMATION;
D O I
10.2174/1574888X13666180723104340
中图分类号
Q813 [细胞工程];
学科分类号
摘要
The nuclear factor kappa B (NF-kappa B) consists of a family of transcription factors involved in the regulation of a wide variety of biological responses. Growing evidence support that NF-kappa B plays a major role in oncogenesis as well as its well-known function in the regulation of immune responses and inflammation. Therefore, we made a review of the diverse molecular mechanisms by which the NF-kappa B pathway is constitutively activated in different types of human cancers and the potential role of various oncogenic genes regulated by this transcription factor in cancer development and progression. We also discussed various pharmacological approaches employed to target the deregulated NF-kappa B signaling pathway and their possible therapeutic potential in cancer therapy. Moreover, Syk (Spleen tyrosine kinase), non-receptor tyrosine kinase which mediates signal transduction downstream of a variety of transmembrane receptors including classical immune-receptors like the B-cell receptor (BCR), which can also activate the inflammasome and NF-kappa B-mediated transcription of chemokines and cytokines in the presence of pathogens would be discussed as well. The highlight of this review article is to summarize the classic and novel signaling pathways involved in NF-kappa B and Syk signaling and then raise some possibilities for cancer therapy.
引用
收藏
页码:219 / 225
页数:7
相关论文
共 74 条
[1]   RETRACTED: A cell cycle regulatory network controlling NF-κB subunit activity and function (Retracted article. See vol. 33, pg. 1978, 2014) [J].
Barre, Benjamin ;
Perkins, Neil D. .
EMBO JOURNAL, 2007, 26 (23) :4841-4855
[2]   RETRACTED: The Skp2 Promoter Integrates Signaling through the NF-κB, p53, and Akt/GSK3β Pathways to Regulate Autophagy and Apoptosis (Retracted article. See vol. 55, pg. 342, 2014) [J].
Barre, Benjamin ;
Perkins, Neil D. .
MOLECULAR CELL, 2010, 38 (04) :524-538
[3]   OPINION Is NF-κB a good target for cancer therapy? Hopes and pitfalls [J].
Baud, Veronique ;
Karin, Michael .
NATURE REVIEWS DRUG DISCOVERY, 2009, 8 (01) :33-40
[4]   Lipopolysaccharide activation of the TPL-2/MEK/extracellular signal-regulated kinase mitogen-activated protein kinase cascade is regulated by IκB kinase-induced proteolysis of NF-κB1 p105 [J].
Beinke, S ;
Robinson, MJ ;
Hugunin, M ;
Ley, SC .
MOLECULAR AND CELLULAR BIOLOGY, 2004, 24 (21) :9658-9667
[5]   The two NF-κB activation pathways and their role in innate and adaptive immunity [J].
Bonizzi, G ;
Karin, M .
TRENDS IN IMMUNOLOGY, 2004, 25 (06) :280-288
[6]   Transcriptional regulation of bcl-2 by nuclear factor κB and its significance in prostate cancer [J].
Catz, SD ;
Johnson, JL .
ONCOGENE, 2001, 20 (50) :7342-7351
[7]   The role of the TRAF-interacting protein in proliferation and differentiation [J].
Chapard, Christophe ;
Hohl, Daniel ;
Huber, Marcel .
EXPERIMENTAL DERMATOLOGY, 2012, 21 (05) :321-326
[8]   The NF-κB-independent functions of IKK subunits in immunity and cancer [J].
Chariot, Alain .
TRENDS IN CELL BIOLOGY, 2009, 19 (08) :404-413
[9]   SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma [J].
Chen, Linfeng ;
Monti, Stefano ;
Juszczynski, Przemyslaw ;
Daley, John ;
Chen, Wen ;
Witzig, Thomas E. ;
Habermann, Thomas M. ;
Kutok, Jeffery L. ;
Shipp, Margaret A. .
BLOOD, 2008, 111 (04) :2230-2237
[10]   The Syk tyrosine kinase: A new negative regulator in tumor growth and progression [J].
Coopman, Peter J. ;
Mueller, Susette C. .
CANCER LETTERS, 2006, 241 (02) :159-173